FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jack Schalken

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Frank P Smit; Sander Jannink; Maciej Salagierski; Jack A Schalken
High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
Daphne Hessels; Jack A Schalken
Urinary biomarkers for prostate cancer: a review.
Maciej Salagierski; Peter Mulders; Jack A Schalken
Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jack Schalken (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Frank P Smit; Sander Jannink; Maciej Salagierski; Jack A Schalken
High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
BJU international 2013;111(5):836-42.
2013: Daphne Hessels; Jack A Schalken
Urinary biomarkers for prostate cancer: a review.
Asian journal of andrology 2013;15(3):333-9.
2013: Maciej Salagierski; Peter Mulders; Jack A Schalken
Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort.
Anticancer research 2013;33(2):553-7.
2013: Jens Hansen; Hartwig Huland; Michael Marberger; Leonard S Marks; Peter F A Mulders; Alan W Partin; Karl Pummer; Jack A Schalken; Shahrokh F Shariat; Arnulf Stenzl; Hendrik van Poppel; Jochen Walz; Clement-Claude Abbou; Sascha A Ahyai; Marco Auprich; Alberto Briganti; Alexandre de la Taille; William Ellis; Margit Fisch; Yves Fradet; Markus Graefen; Alexander Haese; fianceeyi chun
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
European urology 2013;63(2):201-9.
2013: Dick A W Janssen; John P F A Heesakkers; Kees C F J Jansen; Toin H van Kuppevelt; Xander M R van Wijk; Jack A Schalken
The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier.
The Journal of urology 2013;189(1):336-42.
2013: Grégoire Robert; Frank Smit; Tilly W Aalders; Ruben Cremers; Daphne Hessels; Sander Jannink; Peter F A Mulders; Jack A Schalken
Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
The Prostate 2013;73(2):113-20.
2012: Marleen Ansems; Saartje Hontelez; Nina Karthaus; Maaike W G Looman; Jack A Schalken; Gerald W Verhaegh; Tilly W Aalders; Gosse J Adema
DC-SCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells.
The Prostate 2012;72(16):1708-17.
2012: Atish Choudhury; Rosalind Eeles; Stephen J Freedland; William B Isaacs; Mark M Pomerantz; Jack A Schalken; Teuvo L J Tammela; Tapio Visakorpi
The role of genetic markers in the management of prostate cancer.
European urology 2012;62(4):577-87.
2012: Andrea W M Evers; Jan A M Kremer; Maroeska M Rovers; Jack A Schalken; Bas R Bloem; Joris A Veltman; Alain J van Gool
An integrated framework of personalized medicine: from individual genomes to participatory health care.
Croatian medical journal 2012;53(4):301-3.
2012: Maciej Salagierski; Jack A Schalken
Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
The Journal of urology 2012;187(3):795-801.
2012: John Dulos; Sabine Evers; Monika A Gorecka; Willemijn Hobo; Joannes F M Jacobs; Peter Mulders; Egbert Oosterwijk; Cornelis J A Punt; Jack A Schalken; Susan J van Boxtel; Hans van Eenennaam; Gregory J Carven; Anton F J de Haan; Lilian J A Driessen-Engels; Annemieke M Boots
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(2):169-78.
2012: Siebren Dijkstra; Agus Rizal A H Hamid; Gisèle H J M Leyten; Jack A Schalken
Personalized management in low-risk prostate cancer: the role of biomarkers.
Prostate cancer 2012;2012():327104.
2012: Jan Brants; Annaïck Carles; Jan de Mey; Olivier Poch; Karine Pradeau-Aubreton; Aude Robert; Jack A Schalken; Kostyantyn Semenchenko; Christine Wasylyk; Alberto Zambrano; Catherine Birck; Bohdan Wasylyk
Tubulin tyrosine ligase like 12, a TTLL family member with SET- and TTL-like domains and roles in histone and tubulin modifications and mitosis.
PloS one 2012;7(12):e51258.
2012: Agus Rizal A H Hamid; Minja J Pfeiffer; Ewout Schaafsma; John P M Sedelaar; Fred C G J Sweep; Gerald W Verhaegh; Andre Brandt; Jack A Schalken
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Molecular medicine (Cambridge, Mass.) 2012;18():1449-55.
2012: Hirotsugu Uemura; Colleen Nelson; Jack A Schalken; Laurence Klotz
Personalized cancer therapy for urological cancers: from bench to bedside and back.
Advances in urology 2012;2012():298105.
2011: Grégoire Robert; Frank Smit; Tilly Aalders; Alexandre de la Taille; Daphne Hessels; Sander Jannink; Kees Jansen; Herbert F M Karthaus; Peter F A Mulders; Jack A Schalken
Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia.
The Prostate 2011;71(15):1701-9.
2011: Dick A W Janssen; Annemiete W Kemp; John P F A Heesakkers; Joost G Hoenderop; Kees C F J Jansen; Jack A Schalken
The mechanoreceptor TRPV4 is localized in adherence junctions of the human bladder urothelium: a morphological study.
The Journal of urology 2011;186(3):1121-7.
2011: Kamiel A J Kuijpers; John P F A Heesakkers; Theo G M Hafmans; Jack A Schalken
Adherence junctions and cadherin-11 in normal and overactive human detrusor smooth muscle cells.
The Journal of urology 2011;185(5):1946-51.
2011: Gerald W Verhaegh; Arjan S de Jong; Frank P Smit; Sander A Jannink; Willem J G Melchers; Jack A Schalken
Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.
The Prostate 2011;71(4):415-20.
2010: Christine Wasylyk; Alberto Zambrano; Chunhua Zhao; Jan Brants; Joseph Abecassis; Jack A Schalken; Hermann Rogatsch; Georg Schaefer; Armin Pycha; Helmut Klocker; Bohdan Wasylyk
Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy.
International journal of cancer. Journal international du cancer 2010;127(11):2542-53.
2010: Minja J Pfeiffer; Peter F Mulders; Jack A Schalken
An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer.
The Prostate 2010;70(14):1524-32.
2010: Guillaume Ploussard; Alexander Haese; Hendrik Van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Laurence Bastien; Clèment-Claude Abbou; Mesut Remzi; Martina Tinzl; Susan Feyerabend; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken; Alexandre de la Taille
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
BJU international 2010;106(8):1143-7.
2010: Claude C Schulman; Jacques Irani; Juan Morote; Jack A Schalken; Francesco Montorsi; Piotr L Chlosta; Axel Heidenreich
Testosterone measurement in patients with prostate cancer.
European urology 2010;58(1):65-74.
2010: Jack A Schalken
Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development.
European urology 2010;58(1):19-20.
2010: Deborah Vest; Jack A Schalken; Gordon Muir; Prokar Dasgupta
Transmembrane protease serine 2 in prostate cancer.
BJU international 2010;105(11):1490-2.
2010: Minja J Pfeiffer; Jack A Schalken
Stem cell characteristics in prostate cancer cell lines.
European urology 2010;57(2):246-54.
2010: Maciej Salagierski; Gerald W Verhaegh; Sander A Jannink; Frank P Smit; Daphne Hessels; Jack A Schalken
Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer.
The Prostate 2010;70(1):70-8.
2010: Daphne Hessels; Martijn P M Q van Gils; Onno van Hooij; Sander A Jannink; J Alfred Witjes; Gerald W Verhaegh; Jack A Schalken
Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
The Prostate 2010;70(1):10-6.
2009: Martijn P M Q van Gils; Daphne Hessels; W Pim Peelen; Henk Vergunst; Peter F A Mulders; Jack A Schalken
Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
The Prostate 2009;69(15):1624-34.
2009: fianceeyi chun; Alexandre de la Taille; Hendrik van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Clement-Claude Abbou; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken; Yves Fradet; Leonard S Marks; William Ellis; Alan W Partin; Alexander Haese
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
European urology 2009;56(4):659-67.
2009: Jack A Schalken
Editorial comment on: Mutations in the AXIN1 gene in advanced prostate cancer.
European urology 2009;56(3):494.
2009: Scott A Tomlins; Anders Bjartell; Arul M Chinnaiyan; Guido Jenster; Robert K Nam; Mark A Rubin; Jack A Schalken
ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
European urology 2009;56(2):275-86.
2009: Daphne Hessels; Jack A Schalken
The use of PCA3 in the diagnosis of prostate cancer.
Nature reviews. Urology 2009;6(5):255-61.
2009: Ira Kogan-Sakin; Merav Cohen; Nicole Paland; Shalom (Shlomi) Madar; Hilla Solomon; Alina Molchadsky; Ran Brosh; Yosef Buganim; Naomi Goldfinger; Helmut Klocker; Jack A Schalken; Varda Rotter
Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1.
Carcinogenesis 2009;30(4):698-705.
2009: Peter F A Mulders; Jack A Schalken
Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer.
Prostate cancer and prostatic diseases 2009;12(3):241-6.
2008: Jack A Schalken
Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.
European urology 2008;54(6):1438-9.
2008: Leo J Schouten; Boukje van Dijk; Egbert Oosterwijk; Manon van Engeland; Christina A Hulsbergen-van de Kaa; Lambertus A L M Kiemeney; R Alexandra Goldbohm; Arnold Kester; Stefan de Vogel; Jack A Schalken; Piet A van den Brandt
Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(12):3543-50.
2008: Alexander Haese; Alexandre de la Taille; Hendrik van Poppel; Michael Marberger; Arnulf Stenzl; Peter F A Mulders; Hartwig Huland; Clément-Claude Abbou; Mesut Remzi; Martina Tinzl; Susan Feyerabend; Alexander B Stillebroer; Martijn P M Q van Gils; Jack A Schalken
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
European urology 2008;54(5):1081-8.
2008: Martijn P M Q van Gils; Daphne Hessels; Christina A Hulsbergen-van de Kaa; J Alfred Witjes; Cornelius F J Jansen; Peter F A Mulders; Harry G Rittenhouse; Jack A Schalken
Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.
The Prostate 2008;68(11):1215-22.
2008: Paul Span; J Alfred Witjes; Nicolai Grebenchtchikov; Anneke Geurts-Moespot; Paula M J Moonen; Tilly W Aalders; Jessica L J Vriesema; Lambertus A L M Kiemeney; Jack A Schalken; Fred C G J Sweep
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
BJU international 2008;102(2):177-82.
2008: Boukje van Dijk; Leo J Schouten; Egbert Oosterwijk; Christina A Hulsbergen-van de Kaa; Lambertus A L M Kiemeney; R Alexandra Goldbohm; Jack A Schalken; Piet A van den Brandt
Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma.
Cancer causes & control : CCC 2008;19(2):125-34.
2007: Jack A Schalken
Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
European urology 2007;52(6):1679.
2007: Kamiel A J Kuijpers; John P F A Heesakkers; Cornelius F J Jansen; Jack A Schalken
Cadherin-11 is expressed in detrusor smooth muscle cells and myofibroblasts of normal human bladder.
European urology 2007;52(4):1213-21.
2007: Inge van Oort; K Tomita; A van Bokhoven; M J G Bussemakers; Lambertus A L M Kiemeney; Herbert F M Karthaus; J Alfred Witjes; Jack A Schalken
The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study.
The Prostate 2007;67(13):1432-8.
2007: Daphne Hessels; Frank P Smit; Gerald W Verhaegh; J Alfred Witjes; Erik B Cornel; Jack A Schalken
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5103-8.
2007: Keishi Kashibuchi; Kyoichi Tomita; Jack A Schalken; Haruki Kume; Takumi Takeuchi; Tadaichi Kitamura
The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy.
International journal of urology : official journal of the Japanese Urological Association 2007;14(9):789-94.
2007: Paula M J Moonen; Judith M J E Bakkers; Lambertus A L M Kiemeney; Jack A Schalken; Willem J G Melchers; J Alfred Witjes
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer.
European urology 2007;52(2):464-8.
2007: Jack A Schalken
Molecular aspects of hormone-independent prostate cancer.
BJU international 2007;100 Suppl 2():52-5.
2007: Martijn P M Q van Gils; Erik B Cornel; Daphne Hessels; W Pim Peelen; J Alfred Witjes; Peter F A Mulders; Harry G Rittenhouse; Jack A Schalken
Molecular PCA3 diagnostics on prostatic fluid.
The Prostate 2007;67(8):881-7.
2007: Mark A Reynolds; Kumar Kastury; Jack Groskopf; Jack A Schalken; Harry G Rittenhouse
Molecular markers for prostate cancer.
Cancer letters 2007;249(1):5-13.
2007: Martijn P M Q van Gils; Daphne Hessels; Onno van Hooij; Sander A Jannink; W Pim Peelen; Suzanne L J Hanssen; J Alfred Witjes; Erik B Cornel; Herbert F M Karthaus; Geert A H J Smits; Gerhard A Dijkman; Peter F A Mulders; Jack A Schalken
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):939-43.
2007: Nicolas Wicker; Annaïck Carles; Ian Mills; Maija Wolf; Abhi Veerakumarasivam; Henrik Edgren; Fabrice Boileau; Bohdan Wasylyk; Jack A Schalken; David E Neal; Olli Kallioniemi; Olivier Poch
A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH.
BMC genomics 2007;8():84.
2007: Paula M J Moonen; B van Balken-Ory; Lambertus A L M Kiemeney; Jack A Schalken; J Alfred Witjes
Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.
The Journal of urology 2007;177(1):80-3.
2006: Lambertus A L M Kiemeney; Kjeld P van Houwelingen; Manon Bogaerts; J Alfred Witjes; Dorine W Swinkels; Martin den Heijer; Barbara Franke; Jack A Schalken; Gerald W Verhaegh
Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3219-27.
2006: Kristiina Iljin; Maija Wolf; Henrik Edgren; Santosh Gupta; Sami Kilpinen; Rolf Skotheim; Mari Peltola; Frank Smit; Gerald W Verhaegh; Jack A Schalken; Matthias Nees; Olli Kallioniemi
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Cancer research 2006;66(21):10242-6.
2006: Boukje van Dijk; Leo J Schouten; Egbert Oosterwijk; Christina A Hulsbergen-van de Kaa; Lambertus A L M Kiemeney; R Alexandra Goldbohm; Jack A Schalken; Piet A van den Brandt
Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma.
British journal of cancer 2006;95(3):374-7.
2006: Jack A Schalken
Interview with Jack Schalken. PCA3 and its use as a diagnostic test in prostate cancer. Interview by Christine McKillop.
European urology 2006;50(1):153-4.
2006: Barthold Ph Schrier; J L J Vriesema; J Alfred Witjes; Lambertus A L M Kiemeney; Jack A Schalken
The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma.
European urology 2006;50(1):76-82.
2006: Paula M J Moonen; Pim Peelen; Lambertus A L M Kiemeney; Mathilde E Boon; Jack A Schalken; J Alfred Witjes
Quantitative cytology on bladder wash versus voided urine: a comparison of results.
European urology 2006;49(6):1044-9; discussion 1049-50.
2006: Keishi Kashibuchi; Kyoichi Tomita; Jack A Schalken; Haruki Kume; Takuhiro Yamaguchi; Satoru Muto; Sigeo Horie; Tadaichi Kitamura
The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract.
European urology 2006;49(5):839-45; discussion 845.
2006: Ira Kogan; Naomi Goldfinger; Michael Milyavsky; Merav Cohen; Igor Shats; Gabriele Dobler; Helmut Klocker; Bohdan Wasylyk; Maureen Voller; Tilly Aalders; Jack A Schalken; Moshe Oren; Varda Rotter
hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.
Cancer research 2006;66(7):3531-40.
2006: Chaidir A Mochtar; Wijnand Laan; Kjeld P van Houwelingen; Barbara Franke; Jean J M C H de la Rosette; Jack A Schalken; Lambertus A L M Kiemeney
Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
BJU international 2006;97(4):852-5.
2005: Tomonori Habuchi; Michael Marberger; Michael J Droller; George P Hemstreet; H Barton Grossman; Jack A Schalken; Bernd J Schmitz-Dräger; William M Murphy; Aldo V Bono; Peter Goebell; Robert H Getzenberg; Stefan H Hautmann; Edward Messing; Yves Fradet; Vinata B Lokeshwar
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.
Urology 2005;66(6 Suppl 1):64-74.
2005: Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.
Urology 2005;66(6 Suppl 1):35-63.
2005: Jack A Schalken
Validation of molecular targets in prostate cancer.
BJU international 2005;96 Suppl 2():23-9.
2005: Martijn P M Q van Gils; Ulf-Hakan Stenman; Jack A Schalken; Fritz H Schröder; Theo M Luider; Hans Lilja; A Bjartell; Freddie C Hamdy; K S I Pettersson; R Bischoff; H Takalo; O Nilsson; Peter F A Mulders; Chris H Bangma
Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
European urology 2005;48(6):1031-41.
2005: Leo J Schouten; Boukje van Dijk; Egbert Oosterwijk; Christina A Hulsbergen-van de Kaa; Lambertus A L M Kiemeney; R Alexandra Goldbohm; Jack A Schalken; Piet A van den Brandt
Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study.
Journal of hypertension 2005;23(11):1997-2004.
2005: Iman J Schultz; Lambertus A L M Kiemeney; J Alfred Witjes; Jack A Schalken; Johannes L Willems; Dorine W Swinkels; Jacques B de Kok
CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas.
International journal of cancer. Journal international du cancer 2005;116(2):282-4.
2005: Rolph Pfundt; Frank Smit; Corine Jansen; Tilly W Aalders; huub straatman; Walter A Van Der Vliet; John T Isaacs; Ad Geurts van Kessel; Jack A Schalken
Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors.
Genes, chromosomes & cancer 2005;43(3):273-83.
2005: Jack A Schalken; Anders Bergh; Aldo Bono; Christopher Foster; Mary Gospadarowicz; William B Isaacs; Mark Rubin; Fritz Schröder; Bernhard Tribukait; Taiji Tsukamotot; Peter Wiklund
Molecular prostate cancer pathology: current issues and achievements.
Scandinavian journal of urology and nephrology. Supplementum 2005;(216):82-93.
2005: Antoine G van der Heijden; Gerald W Verhaegh; Cornelius F J Jansen; Jack A Schalken; J Alfred Witjes
Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
The Journal of urology 2005;173(4):1375-80.
2005: Kjeld P van Houwelingen; Boukje van Dijk; Christina A Hulsbergen-van de Kaa; Leo J Schouten; Hanneke J M Gorissen; Jack A Schalken; Piet A van den Brandt; Egbert Oosterwijk
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
BMC cancer 2005;5():57.
2004: Antoine G van der Heijden; Cornelius F J Jansen; Gerald W Verhaegh; Michael A O'donnell; Jack A Schalken; J Alfred Witjes
The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines.
European urology 2004;46(5):670-4.
2004: Karin Grabmaier; Mirjam C A de Weijert; Gerald W Verhaegh; Jack A Schalken; Egbert Oosterwijk
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
Oncogene 2004;23(33):5624-31.
2004: Daphne Hessels; Gerald W Verhaegh; Jack A Schalken; J Alfred Witjes
Applicability of biomarkers in the early diagnosis of prostate cancer.
Expert review of molecular diagnostics 2004;4(4):513-26.
2004: Naoko Konno-Takahashi; Takumi Takeuchi; Hiroaki Nishimatsu; Toshiyuki Kamijo; Kyoichi Tomita; Jack A Schalken; Shinichi Teshima; Tadaichi Kitamura
Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe.
European urology 2004;46(1):126-32.
2004: Bas A J Verhage; Katja K H Aben; J Alfred Witjes; huub straatman; Jack A Schalken; Lambertus A L M Kiemeney
Site-specific familial aggregation of prostate cancer.
International journal of cancer. Journal international du cancer 2004;109(4):611-7.
2004: Jody E Nuininga; H T B van Moerkerk; A Hanssen; CA Hulsbergen; Jeannette C Oosterwijk-Wakka; Egbert Oosterwijk; R P E de Gier; Jack A Schalken; Toin H van Kuppevelt; W F J Feitz
A rabbit model to tissue engineer the bladder.
Biomaterials 2004;25(9):1657-61.
2004: Paul Abrams; Jack A Schalken
Etiology and management of pelvic pain syndrome.
Urology 2004;63(3 Suppl 1):74.
2004: Jack A Schalken
Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia.
BJU international 2004;93 Suppl 1():5-9.
2004: J Alfred Witjes; Antoine G van der Heijden; J L J Vriesema; G J Peters; A Laan; Jack A Schalken
Intravesical gemcitabine: a phase 1 and pharmacokinetic study.
European urology 2004;45(2):182-6.
2004: Toru Shimazui; Jack A Schalken; Koji Kawai; Risa Kawamoto; Adrie van Bockhoven; Egbert Oosterwijk; Hideyuki Akaza
Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines.
Oncology reports 2004;11(2):357-60.
2003: Jack A Schalken; Daphne Hessels; Gerald W Verhaegh
New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene.
Urology 2003;62(5 Suppl 1):34-43.
2003: Jack A Schalken; Geert J L H van Leenders
Cellular and molecular biology of the prostate: stem cell biology.
Urology 2003;62(5 Suppl 1):11-20.
2003: J Alfred Witjes; J L J Vriesema; Antoine G van der Heijden; G J Peters; Jack A Schalken
Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
European urology 2003;44(5):615-9.
2003: Hong Zheng; Christine Wasylyk; Abdelkader Ayadi; Joseph Abecassis; Jack A Schalken; Hermann Rogatsch; Nicolas Wernert; Sauveur-Michel Maira; Marie-Christine Multon; Bohdan Wasylyk
The transcription factor Net regulates the angiogenic switch.
Genes & development 2003;17(18):2283-97.
2003: Jody E Nuininga; H T B van Moerkerk; A Hanssen; CA Hulsbergen; Jeannette C Oosterwijk-Wakka; Egbert Oosterwijk; R P E de Gier; Jack A Schalken; Toin H van Kuppevelt; W F J Feitz
Rabbit urethra replacement with a defined biomatrix or small intestinal submucosa.
European urology 2003;44(2):266-71.
2003: Iman J Schultz; Lambertus A L M Kiemeney; J Alfred Witjes; Jack A Schalken; Johannes L Willems; Dorine W Swinkels; Jacques B de Kok
Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
Anticancer research 2003;23(4):3327-31.
2003: Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L H van Leenders; Bianca van Balken; Lambertus A L M Kiemeney; J Alfred Witjes; Jack A Schalken
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.
European urology 2003;44(1):8-15; discussion 15-6.
2003: Geert J L H van Leenders; Jack A Schalken
Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer.
Critical reviews in oncology/hematology 2003;46 Suppl():S3-10.
2003: Geert J L H van Leenders; Wesley R Gage; Jessica L Hicks; Bianca van Balken; Tilly W Aalders; Jack A Schalken; Angelo M DeMarzo
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.
The American journal of pathology 2003;162(5):1529-37.
2003: Bas A J Verhage; Kjeld Van Houwelingen; T Emiel G Ruijter; Lambertus A L M Kiemeney; Jack A Schalken
Allelic imbalance in hereditary and sporadic prostate cancer.
The Prostate 2003;54(1):50-7.
2002: Erik Teske; E C Naan; E M van Dijk; Evert van Garderen; Jack A Schalken
Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs.
Molecular and cellular endocrinology 2002;197(1-2):251-5.
2002: Evert van Garderen; Jack A Schalken
Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system.
Molecular and cellular endocrinology 2002;197(1-2):153-65.
2002: Chie Sugimoto; Masami Hasegawa; Huai-Ying Zheng; Vladimir Demenev; Yoshiharu Sekino; Kazuo Kojima; Takeo Honjo; Hiroshi Kida; Tapani Hovi; Timo Vesikari; Jack A Schalken; Kyoichi Tomita; Yukari Mitsunobu; Hiroshi Ikegaya; Nobuyoshi Kobayashi; Tadaichi Kitamura; Yoshiaki Yogo
JC virus strains indigenous to northeastern Siberians and Canadian Inuits are unique but evolutionally related to those distributed throughout Europe and Mediterranean areas.
Journal of molecular evolution 2002;55(3):322-35.
2002: Bas A J Verhage; Kjeld Van Houwelingen; T Emiel G Ruijter; Lambertus A L M Kiemeney; Jack A Schalken
Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer.
International journal of cancer. Journal international du cancer 2002;100(6):683-5.
2002: Karin Grabmaier; Mirjam de Weijert; Hirotsugu Uemura; Jack A Schalken; Egbert Oosterwijk
Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies.
Urology 2002;60(2):357-62.
2002: Jacques B de Kok; Gerald W Verhaegh; Rian W Roelofs; Daphne Hessels; Lambertus A L M Kiemeney; Tilly W Aalders; Dorine W Swinkels; Jack A Schalken
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
Cancer research 2002;62(9):2695-8.
2002: Geert J L H van Leenders; Bianca van Balken; Tilly W Aalders; Christina A Hulsbergen-van de Kaa; Dirk J Ruiter; Jack A Schalken
Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion.
The Prostate 2002;51(2):98-107.
2002: Ron J T Van Golde; Kjeld Van Houwelingen; Lambertus A L M Kiemeney; Jan Kremer; Joep H A M Tuerlings; Jack A Schalken; E J H Meuleman
Is increased CAG repeat length in the androgen receptor gene a risk factor for male subfertility?
The Journal of urology 2002;167(2 Pt 1):621-3.
2002: Boukje van Dijk; Leo J Schouten; Christina A Hulsbergen-van de Kaa; Kjeld P van Houwelingen; Jack A Schalken; Lambertus A L M Kiemeney; A H M Geurts van Kessel; R A Bausch-Goldbohm; Piet A van den Brandt
Risk factors, genetic predisposition and mutations in the VHL gene in sporadic renal cell carcinoma: The Netherlands Cohort Study.
IARC scientific publications 2002;156():509-10.
2002: P H M De Mulder; Jack A Schalken; C N Sternberg
Treatment options in hormone resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 4():95-102.
2001: Geert J L H van Leenders; Tilly W Aalders; Christina A Hulsbergen-van de Kaa; Dirk J Ruiter; Jack A Schalken
Expression of basal cell keratins in human prostate cancer metastases and cell lines.
The Journal of pathology 2001;195(5):563-70.
2001: Boukje van Dijk; Kjeld Van Houwelingen; J Alfred Witjes; Jack A Schalken; Lambertus A L M Kiemeney
Alcohol dehydrogenase type 3 (ADH3) and the risk of bladder cancer.
European urology 2001;40(5):509-14.
2001: Y Xue; Gabe S Sonke; Coen Schoots; Jack A Schalken; Albert A J Verhofstad; Jean J M C H de la Rosette; Frank Smedts
Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth.
The Prostate 2001;49(2):132-9.
2001: Geert J L H van Leenders; Jack A Schalken
Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis.
BJU international 2001;88 Suppl 2():35-42; discussion 49-50.
2001: J L J Vriesema; F Atsma; Lambertus A L M Kiemeney; W Pim Peelen; J Alfred Witjes; Jack A Schalken
Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence.
Urology 2001;58(3):367-71.
2001: J L J Vriesema; Katja K H Aben; J Alfred Witjes; Lambertus A L M Kiemeney; Jack A Schalken
Superficial and metachronous invasive bladder carcinomas are clonally related.
International journal of cancer. Journal international du cancer 2001;93(5):699-702.
2001: W Mahapokai; T S G A M van den Ingh; Frans van Mil; Evert van Garderen; Jack A Schalken; Jan A Mol; Frederik J van Sluijs
Immune response in hormonally-induced prostatic hyperplasia in the dog.
Veterinary immunology and immunopathology 2001;78(3-4):297-303.
2001: Evert van Garderen; joost swennenhuis; Eva Hellmén; Jack A Schalken
Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells.
Domestic animal endocrinology 2001;20(2):123-35.
2001: ET Ruijter; R Montironi; CA van de Kaa; Jack A Schalken
Molecular changes associated with prostate cancer development.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 2001;23(1):67-88.
2001: Y Xue; Frank Smedts; ET Ruijter; Frans M J Debruyne; Jean J M C H de la Rosette; Jack A Schalken
Branching activity in the human prostate: a closer look at the structure of small glandular buds.
European urology 2001;39(2):222-31.
2000: Katja K H Aben; J Alfred Witjes; J A A M van Dijck; Jack A Schalken; André L M Verbeek; Lambertus A L M Kiemeney
Lower incidence of urothelial cell carcinoma due to the concept of a clonal origin.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2385-9.
2000: Gerald W Verhaegh; A van Bokhoven; F Smit; Jack A Schalken; M J G Bussemakers
Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene.
The Journal of biological chemistry 2000;275(48):37496-503.
2000: Henk G van der Poel; Bas W G van Rhijn; Pim Peelen; Frans M J Debruyne; Mathilde E Boon; Jack A Schalken
Consecutive quantitative cytology in bladder cancer.
Urology 2000;56(4):584-8.
2000: Raymond G Schipper; G Deli; P Deloyer; W P Lange; Jack A Schalken; Albert A J Verhofstad
Antitumor activity of the polyamine analog N(1), N(11)-diethylnorspermine against human prostate carcinoma cells.
The Prostate 2000;44(4):313-21.
2000: J L J Vriesema; Henk G van der Poel; Frans M J Debruyne; Jack A Schalken; L P Kok; Mathilde E Boon
Neural network-based digitized cell image diagnosis of bladder wash cytology.
Diagnostic cytopathology 2000;23(3):171-9.
2000: Toru Shimazui; Jeannette C Oosterwijk-Wakka; Hideyuki Akaza; PP Bringuier; ET Ruijter; Frans M J Debruyne; Jack A Schalken; Egbert Oosterwijk
Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma.
European urology 2000;38(3):331-8.
2000: Jacques B de Kok; Jack A Schalken; Tilly W Aalders; T J M Ruers; Hans L Willems; Dorine W Swinkels
Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas.
International journal of cancer. Journal international du cancer 2000;87(2):217-20.
2000: K Tomita; A van Bokhoven; Geert J L H van Leenders; ET Ruijter; CF Jansen; M J G Bussemakers; Jack A Schalken
Cadherin switching in human prostate cancer progression.
Cancer research 2000;60(13):3650-4.
2000: Marinette van der Graaf; Raymond G Schipper; GO Oosterhof; Jack A Schalken; Albert A J Verhofstad; Arend Heerschap
Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer.
Magma (New York, N.Y.) 2000;10(3):153-9.
2000: W Mahapokai; Y Xue; Evert van Garderen; Frederik J van Sluijs; Jan A Mol; Jack A Schalken
Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog.
The Prostate 2000;44(1):40-8.
2000: LA Giroldi; Toru Shimazui; Jack A Schalken; H Yamasaki; PP Bringuier
Classical cadherins in urological cancers.
Morphologie : bulletin de l'Association des anatomistes 2000;84(265):31-8.
2000: Bas W G van Rhijn; Henk G van der Poel; Mathilde E Boon; Frans M J Debruyne; Jack A Schalken; J Alfred Witjes
Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.
Urology 2000;55(3):363-7.
2000: M J G Bussemakers; A van Bokhoven; K Tomita; CF Jansen; Jack A Schalken
Complex cadherin expression in human prostate cancer cells.
International journal of cancer. Journal international du cancer 2000;85(3):446-50.
2000: Y Xue; Jeroen A W M van der Laak; Frank Smedts; Coen Schoots; Albert A J Verhofstad; Jean J M C H de la Rosette; Jack A Schalken
Neuroendocrine cells during human prostate development: does neuroendocrine cell density remain constant during fetal as well as postnatal life?
The Prostate 2000;42(2):116-23.
2000: K Tomita; A van Bokhoven; CF Jansen; M J G Bussemakers; Jack A Schalken
Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin.
Biochemical and biophysical research communications 2000;267(3):870-4.
1999: M J G Bussemakers; A van Bokhoven; Gerald W Verhaegh; F P Smit; Herbert F M Karthaus; Jack A Schalken; Frans M J Debruyne; N Ru; William B Isaacs
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Cancer research 1999;59(23):5975-9.
1999: Evert van Garderen; H J van der Poel; joost swennenhuis; E H Wissink; Gerard Rutteman; Eva Hellmén; Jan A Mol; Jack A Schalken
Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors.
Endocrinology 1999;140(12):5907-14.
1999: PP Bringuier; LA Giroldi; R Umbas; Toru Shimazui; Jack A Schalken
Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors.
International journal of cancer. Journal international du cancer 1999;83(5):591-5.
1999: Jan A Mol; Irma S Lantinga-van Leeuwen; Evert van Garderen; PJ Selman; Marja A Oosterlaken-Dijksterhuis; Jack A Schalken; Ad Rijnberk
Mammary growth hormone and tumorigenesis--lessons from the dog.
The Veterinary quarterly 1999;21(4):111-5.
1999: LA Giroldi; PP Bringuier; Toru Shimazui; K Jansen; Jack A Schalken
Changes in cadherin-catenin complexes in the progression of human bladder carcinoma.
International journal of cancer. Journal international du cancer 1999;82(1):70-6.
1999: ET Ruijter; Gary J Miller; CA van de Kaa; A van Bokhoven; M J G Bussemakers; Frans M J Debruyne; Dirk J Ruiter; Jack A Schalken
Molecular analysis of multifocal prostate cancer lesions.
The Journal of pathology 1999;188(3):271-7.
1999: ET Ruijter; CA van de Kaa; G Miller; Dirk J Ruiter; Frans Debruyne; Jack A Schalken
Molecular genetics and epidemiology of prostate carcinoma.
Endocrine reviews 1999;20(1):22-45.
1999: Y Xue; Jeroen A W M van der Laak; MA Latijnhouwers; Frank Smedts; Henk G van der Poel; Jean J M C H de la Rosette; Frans M J Debruyne; Jack A Schalken
Transient tenascin enhancement is an early event after androgen ablation in rat prostate.
Urological research 1999;27(1):9-15.
1998: Jacqueline Vet; Daphne Hessels; Salvatore A E Marras; CA van de Kaa; Henk G van der Poel; R J Michalides; Frans M J Debruyne; Jack A Schalken
Comparative analysis of p53 mutations in bladder washings and histologic specimens.
American journal of clinical pathology 1998;110(5):647-52.
1998: Toru Shimazui; Egbert Oosterwijk; Hideyuki Akaza; PP Bringuier; ET Ruijter; H van Berkel; J O Wakka; A van Bokhoven; Frans M J Debruyne; Jack A Schalken
Expression of cadherin-6 as a novel diagnostic tool to predict prognosis of patients with E-cadherin-absent renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2419-24.
1998: ET Ruijter; Priya N Werahera; CA van de Kaa; J Scott Stewart; Jack A Schalken; Gary J Miller
Detection of abnormal E-cadherin expression by simulated prostate biopsy.
The Journal of urology 1998;160(4):1368-71; discussion 1371-2.
1998: Denis H J Schamhart; Theo M de Reijke; Henk G van der Poel; J Alfred Witjes; Elizabeth C De Boer; Karl-Heinz Kurth; Jack A Schalken
The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
European urology 1998;34(2):99-106.
1998: Y Xue; Frank Smedts; MA Latijnhouwers; ET Ruijter; Tilly W Aalders; Jean J M C H de la Rosette; Frans M J Debruyne; Jack A Schalken
Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression?
Anticancer research 1998;18(4A):2679-84.
1998: Henk G van der Poel; Daphne Hessels; Geert J L H van Leenders; M J G Bussemakers; Jack A Schalken; J Alfred Witjes; Frans M J Debruyne
Multifocal transitional cell cancer and p53 mutation analysis.
The Journal of urology 1998;160(1):124-5.
1998: Y Xue; J Li; MA Latijnhouwers; Frank Smedts; R Umbas; Tilly W Aalders; Frans M J Debruyne; Jean J M C H de la Rosette; Jack A Schalken
Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma.
British journal of urology 1998;81(6):844-51.
1998: ET Ruijter; CA van de Kaa; Tilly W Aalders; Dirk J Ruiter; G Miller; Frans Debruyne; Jack A Schalken
Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1998;11(3):276-81.
1998: Y Xue; Frank Smedts; Frans M J Debruyne; Jean J M C H de la Rosette; Jack A Schalken
Identification of intermediate cell types by keratin expression in the developing human prostate.
The Prostate 1998;34(4):292-301.
1998: Jack A Schalken
Molecular diagnostics and therapy of prostate cancer: new avenues.
European urology 1998;34 Suppl 3():3-6.
1998: Y Xue; Frank Smedts; Albert A J Verhofstad; Frans Debruyne; Jean J M C H de la Rosette; Jack A Schalken
Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives.
The Prostate. Supplement 1998;8():62-73.
1998: Jack A Schalken
Molecular prognostic factors in bladder cancer.
European urology 1998;33 Suppl 4():13-4.
1998: J Alfred Witjes; Henk G van der Poel; MR van Balken; Frans M J Debruyne; Jack A Schalken
Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer.
European urology 1998;33(4):387-91.
1998: Henk G van der Poel; MR van Balken; Denis H J Schamhart; Pim Peelen; T de Reijke; Frans M J Debruyne; Jack A Schalken; J Alfred Witjes
Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer.
Urology 1998;51(1):44-50.
1997: LA Giroldi; PP Bringuier; Mirjam de Weijert; C Jansen; A van Bokhoven; Jack A Schalken
Role of E boxes in the repression of E-cadherin expression.
Biochemical and biophysical research communications 1997;241(2):453-8.
1997: Y Xue; Albert A J Verhofstad; W Lange; Frank Smedts; Frans Debruyne; Jean J M C H de la Rosette; Jack A Schalken
Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate.
The American journal of pathology 1997;151(6):1759-65.
1997: David F Jarrard; R Paul; A van Bokhoven; SH Nguyen; G Steven Bova; M J Wheelock; K R Johnson; Jack A Schalken; M J G Bussemakers; William B Isaacs
P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2121-8.
1997: ET Ruijter; Gary J Miller; Tilly W Aalders; CA van de Kaa; Jack A Schalken; Frans M J Debruyne; M E Boon
Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group.
The Journal of pathology 1997;183(3):369-75.
1997: Toru Shimazui; PP Bringuier; H van Berkel; ET Ruijter; Hideyuki Akaza; Frans M J Debruyne; Egbert Oosterwijk; Jack A Schalken
Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma.
International journal of cancer. Journal international du cancer 1997;74(5):523-8.
1997: Henk G van der Poel; Mathilde E Boon; P van Stratum; E C Ooms; H Wiener; Frans M J Debruyne; J Alfred Witjes; Jack A Schalken; W M Murphy
Conventional bladder wash cytology performed by four experts versus quantitative image analysis.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1997;10(10):976-82.
1997: R Umbas; William B Isaacs; PP Bringuier; Y Xue; Frans M J Debruyne; Jack A Schalken
Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer.
International journal of cancer. Journal international du cancer 1997;74(4):374-7.
1997: M Linkels; M J G Bussemakers; F Nollet; C M Ewing; F van Roy; Jack A Schalken
Molecular cloning of an alternative human alphaE-catenin cDNA.
Biochemical and biophysical research communications 1997;237(1):177-81.
1997: Henk G van der Poel; GO Oosterhof; H E Schaafsma; Frans M J Debruyne; Jack A Schalken
Intratumoral nuclear morphologic heterogeneity in prostate cancer.
Urology 1997;49(4):652-7.
1997: Jacqueline Vet; R J van Moorselaar; Frans M J Debruyne; Jack A Schalken
Differential expression of ferritin heavy chain in a rat transitional cell carcinoma progression model.
Biochimica et biophysica acta 1997;1360(1):39-44.
1997: Y Xue; Frank Smedts; R Umbas; Tilly W Aalders; Frans M J Debruyne; Jean J M C H de la Rosette; Jack A Schalken
Changes in keratin expression during the development of benign prostatic hyperplasia.
European urology 1997;32(3):332-8.
1997: GO Oosterhof; Erik B Cornel; G A Smits; Frans M J Debruyne; Jack A Schalken
Influence of high-intensity focused ultrasound on the development of metastases.
European urology 1997;32(1):91-5.
1997: Jack A Schalken
New perspectives in the treatment of prostate cancer.
European urology 1997;31 Suppl 2():20-3.
1996: ET Ruijter; CA van de Kaa; Jack A Schalken; F M Debruyne; Dirk J Ruiter
Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications.
The Journal of pathology 1996;180(3):295-9.
1996: Toru Shimazui; Egbert Oosterwijk; F M Debruyne; Jack A Schalken
Molecular prognostic factor in renal cell carcinoma.
Seminars in urologic oncology 1996;14(4):250-5.
1996: Y Tamimi; PP Bringuier; F Smit; A van Bokhoven; A Abbas; F M Debruyne; Jack A Schalken
Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer.
International journal of cancer. Journal international du cancer 1996;68(2):183-7.
1996: Toru Shimazui; Jack A Schalken; LA Giroldi; C F Jansen; H Akaza; K Koiso; F M Debruyne; PP Bringuier
Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors.
Cancer research 1996;56(18):4154-8.
1996: Henk G van der Poel; J Alfred Witjes; P van Stratum; M E Boon; F M Debruyne; Jack A Schalken
Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer.
Urology 1996;48(3):357-64.
1996: Y Tamimi; H G van der Poel; Herbert F M Karthaus; F M Debruyne; Jack A Schalken
A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization.
British journal of cancer 1996;74(4):573-8.
1996: Toru Shimazui; LA Giroldi; PP Bringuier; Egbert Oosterwijk; Jack A Schalken
Complex cadherin expression in renal cell carcinoma.
Cancer research 1996;56(14):3234-7.
1996: Y Tamimi; PP Bringuier; F Smit; A van Bokhoven; F M Debruyne; Jack A Schalken
p16 mutations/deletions are not frequent events in prostate cancer.
British journal of cancer 1996;74(1):120-2.
1996: Jacqueline Vet; J Alfred Witjes; Salvatore A E Marras; Daphne Hessels; Henk G van der Poel; F M Debruyne; Jack A Schalken
Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):1055-61.
1996: P J Poddighe; PP Bringuier; M Vallinga; Jack A Schalken; Frans C S Ramaekers; Anton H N Hopman
Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysis.
The Journal of pathology 1996;179(2):169-76.
1996: PP Bringuier; Y Tamimi; E Schuuring; Jack A Schalken
Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification.
Oncogene 1996;12(8):1747-53.
1996: M J G Bussemakers; Jack A Schalken
The role of cell adhesion molecules and proteases in tumor invasion and metastasis.
World journal of urology 1996;14(3):151-6.
1996: GO Oosterhof; Erik B Cornel; G A Smits; F M Debruyne; Jack A Schalken
The influence of high-energy shock waves on the development of metastases.
Ultrasound in medicine & biology 1996;22(3):339-44.
1995: Jacqueline Vet; PP Bringuier; H E Schaafsma; J Alfred Witjes; F M Debruyne; Jack A Schalken
Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.
Laboratory investigation; a journal of technical methods and pathology 1995;73(6):837-43.
1995: J Alfred Witjes; R Umbas; F M Debruyne; Jack A Schalken
Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer.
The Journal of urology 1995;154(6):2185-9.
1995: Gerda Smets; R Van Ginckel; G Daneels; M Moeremans; J Van Wauwe; M C Coene; Frans C S Ramaekers; Jack A Schalken; Marcel Borgers; R De Coster
Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid.
The Prostate 1995;27(3):129-40.
1995: C Voorter; Stefan Joos; PP Bringuier; M Vallinga; P Poddighe; Jack A Schalken; S du Manoir; Frans C S Ramaekers; P Lichter; Anton H N Hopman
Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization.
The American journal of pathology 1995;146(6):1341-54.
1995: J L Beck; Anton H N Hopman; W F J Feitz; Jack A Schalken; H E Schaafsma; CA van de Kaa; Frans C S Ramaekers; A G J M Hanselaar; Peter C M de Wilde
Numerical aberrations of chromosomes 1 and 7 in renal cell carcinomas as detected by interphase cytogenetics.
The Journal of pathology 1995;176(2):123-35.
1995: Erik B Cornel; G A Smits; J E de Ruijter; GO Oosterhof; A Heerschap; F M Debruyne; Jack A Schalken
In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines.
The Prostate 1995;26(5):275-80.
1995: Erik B Cornel; G A Smits; F M Debruyne; A Heerschap; Jack A Schalken; GO Oosterhof
The effects of successive high-energy shock-wave tumor administration on tumor blood flow.
Ultrasound in medicine & biology 1995;21(2):243-8.
1994: Erik B Cornel; Egbert Oosterwijk; J D van de Streek; G Grutters; F M Debruyne; Jack A Schalken; GO Oosterhof
High energy shock waves induced increase in the local concentration of systemically given TNF-alpha.
The Journal of urology 1994;152(6 Pt 1):2164-6.
1994: G A Smits; Erik B Cornel; E van de Boogert; GO Oosterhof; F M Debruyne; Jack A Schalken; A Heerschap
Effects of high energy shock waves on tumor blood flow and metabolism: 31P/1H/2H nuclear magnetic resonance study.
NMR in biomedicine 1994;7(7):319-26.
1994: M J G Bussemakers; A van Bokhoven; M Völler; F P Smit; Jack A Schalken
The genes for the calcium-dependent cell adhesion molecules P- and E-cadherin are tandemly arranged in the human genome.
Biochemical and biophysical research communications 1994;203(2):1291-4.
1994: M J G Bussemakers; LA Giroldi; A van Bokhoven; Jack A Schalken
Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter.
Biochemical and biophysical research communications 1994;203(2):1284-90.
1994: Jacqueline Vet; PP Bringuier; P J Poddighe; Herbert F M Karthaus; F M Debruyne; Jack A Schalken
p53 mutations have no additional prognostic value over stage in bladder cancer.
British journal of cancer 1994;70(3):496-500.
1994: Henk G van der Poel; P F Mulders; T W Aalders; GO Oosterhof; F M Debruyne; Jack A Schalken
Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma.
Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 1994;7(2):153-70.
1994: R Umbas; William B Isaacs; PP Bringuier; H E Schaafsma; Herbert F M Karthaus; GO Oosterhof; F M Debruyne; Jack A Schalken
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Cancer research 1994;54(14):3929-33.
1994: Erik B Cornel; A Heerschap; G A Smits; GO Oosterhof; F M Debruyne; Jack A Schalken
Magnetic resonance spectroscopy detects metabolic differences between seven Dunning rat prostate tumor sublines with different biological behavior.
The Prostate 1994;25(1):19-28.
1994: G A Dijkman; R J Van Moorselaar; R Van Ginckel; P Van Stratum; Luc Wouters; F M Debruyne; Jack A Schalken; R de Coster
Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
The Journal of urology 1994;151(1):217-22.
1994: Jacqueline Vet; F M Debruyne; Jack A Schalken
Molecular prognostic factors in bladder cancer.
World journal of urology 1994;12(2):84-8.
1994: Henk G van der Poel; P F Mulders; GO Oosterhof; H E Schaafsma; Jan C M Hendriks; Jack A Schalken; F M Debruyne
Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal-cell carcinoma.
Investigative urology (Berlin, Germany) 1994;5():60-5.
1994: LA Giroldi; PP Bringuier; Jack A Schalken
Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms.
Invasion & metastasis 1994;14(1-6):71-81.
1993: Erik B Cornel; G A Smits; GO Oosterhof; Herbert F M Karthaus; F M Deburyne; Jack A Schalken; A Heerschap
Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy.
The Journal of urology 1993;150(6):2019-24.
1993: Y Tamimi; H G van der Poel; M M Denyn; R Umbas; Herbert F M Karthaus; F M Debruyne; Jack A Schalken
Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.
Cancer research 1993;53(22):5512-6.
1993: Henk G van der Poel; P F Mulders; GO Oosterhof; H E Schaafsma; Jan C M Hendriks; Jack A Schalken; F M Debruyne
Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity.
Cancer 1993;72(9):2667-74.
1993: Henk G van der Poel; GO Oosterhof; F M Debruyne; Jack A Schalken
Image analysis in superficial transitional cell carcinoma of the bladder.
Seminars in urology 1993;11(3):164-70.
1993: PP Bringuier; R Umbas; H E Schaafsma; Herbert F M Karthaus; F M Debruyne; Jack A Schalken
Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
Cancer research 1993;53(14):3241-5.
1993: LA Giroldi; Jack A Schalken
Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications.
Cancer metastasis reviews 1993;12(1):29-37.
1993: M J G Bussemakers; A van Bokhoven; S G Mees; R Kemler; Jack A Schalken
Molecular cloning and characterization of the human E-cadherin cDNA.
Molecular biology reports 1993;17(2):123-8.
1993: Erik B Cornel; R J Van Moorselaar; P Van Stratum; F M Debruyne; Jack A Schalken
Antitumor effects of bacillus Calmette-Guerin in a syngeneic rat bladder tumor model system, RBT323.
The Journal of urology 1993;149(1):179-82.
1993: G A Smits; P H Jap; A Heerschap; GO Oosterhof; F M Debruyne; Jack A Schalken
Biological effects of high energy shock waves in mouse skeletal muscle: correlation between 31P magnetic resonance spectroscopic and microscopic alterations.
Ultrasound in medicine & biology 1993;19(5):399-409.
1993: R J van Moorselaar; T Ichikawa; H E Schaafsma; P H Jap; John T Isaacs; P van Stratum; Frans C S Ramaekers; F M Debruyne; Jack A Schalken
The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma.
Urological research 1993;21(6):413-21.
1992: A P Verhagen; Frans C S Ramaekers; Tilly W Aalders; H E Schaafsma; F M Debruyne; Jack A Schalken
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer.
Cancer research 1992;52(22):6182-7.
1992: R Umbas; Jack A Schalken; Tilly W Aalders; B S Carter; Herbert F M Karthaus; H E Schaafsma; F M Debruyne; William B Isaacs
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Cancer research 1992;52(18):5104-9.
1992: Jack A Schalken; R J van Moorselaar; PP Bringuier; F M Debruyne
Critical review of the models to study the biologic progression of bladder cancer.
Seminars in surgical oncology 1992;8(5):274-8.
1992: R J van Moorselaar; B T Hendriks; G Borm; P H van der Meide; F M Debruyne; Jack A Schalken
Inhibition of rat bladder tumor (RBT323) growth by tumor necrosis factor alpha and interferon-gamma in vivo.
The Journal of urology 1992;148(2 Pt 1):458-62.
1992: Henk G van der Poel; H E Schaafsma; G P Vooijs; F M Debruyne; Jack A Schalken
Quantitative light microscopy in urological oncology.
The Journal of urology 1992;148(1):1-13.
1992: M J G Bussemakers; R J van Moorselaar; LA Giroldi; T Ichikawa; John T Isaacs; M Takeichi; F M Debruyne; Jack A Schalken
Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Cancer research 1992;52(10):2916-22.
1992: M J G Bussemakers; G W Verhaegh; A van Bokhoven; F M Debruyne; Jack A Schalken
Differential expression of vimentin in rat prostatic tumors.
Biochemical and biophysical research communications 1992;182(3):1254-9.
1992: A J Beniers; W P Peelen; H E Schaafsma; J L Beck; Frans C S Ramaekers; F M Debruyne; Jack A Schalken
Establishment and characterization of five new human renal tumor xenografts.
The American journal of pathology 1992;140(2):483-95.
1992: M J G Bussemakers; A van Bokhoven; J J van Groningen; F M Debruyne; Jack A Schalken
Increased expression of retroviral sequences in progressionally advanced rat prostatic tumors.
Biochemical and biophysical research communications 1992;182(1):318-24.
1992: Henk G van der Poel; R D van Caubergh; M E Boon; F M Debruyne; Jack A Schalken
Karyometry in recurrent superficial transitional cell tumors of the bladder.
Urological research 1992;20(5):375-81.
1992: Jack A Schalken; F M Debruyne
Identification of new prostate cancer progression markers by differential hybridization analysis.
European urology 1992;21 Suppl 1():60-5.
1992: Henk G van der Poel; GO Oosterhof; H E Schaafsma; A Wiersma-van Tilburg; F M Debruyne; Jack A Schalken
Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladder.
Progress in clinical and biological research 1992;378():9-18.
1991: H E Schaafsma; Frans C S Ramaekers; Goos N P van Muijen; H Robben; E B Lane; I M Leigh; E C Ooms; Jack A Schalken; R J van Moorselaar; Dirk J Ruiter
Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases.
The American journal of pathology 1991;139(6):1389-400.
1991: A J Beniers; W P Peelen; F M Debruyne; Jack A Schalken
HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF.
International journal of cancer. Journal international du cancer 1991;48(5):709-16.
1991: R J van Moorselaar; B T Hendriks; P van Stratum; P H van der Meide; F M Debruyne; Jack A Schalken
Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumors.
Cancer research 1991;51(9):2329-34.
1991: G A Smits; GO Oosterhof; A E de Ruyter; Jack A Schalken; F M Debruyne
Cytotoxic effects of high energy shock waves in different in vitro models: influence of the experimental set-up.
The Journal of urology 1991;145(1):171-5.
1991: GO Oosterhof; G A Smits; A E de Ruyter; Jack A Schalken; F M Debruyne
Effects of high-energy shock waves combined with biological response modifiers in different human kidney cancer xenografts.
Ultrasound in medicine & biology 1991;17(4):391-9.
1991: A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; Jack A Schalken
Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.
Urological research 1991;19(2):91-8.
1991: R J van Moorselaar; P van Stratum; G Borm; F M Debruyne; Jack A Schalken
Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice.
The Prostate 1991;18(4):331-44.
1991: G A Smits; A Heerschap; GO Oosterhof; J H Ruys; C W Hilbers; F M Debruyne; Jack A Schalken
Early metabolic response to high energy shock waves in a human tumor kidney xenograft monitored by 31P magnetic resonance spectroscopy.
Ultrasound in medicine & biology 1991;17(8):791-801.
1990: R J Van Moorselaar; J H Schwachöfer; R P Crooijmans; P Van Stratum; F M Debruyne; Jack A Schalken
Combined effects of tumor necrosis factor alpha and radiation in the treatment of renal cell carcinoma grown as radia spheroids.
Anticancer research 1990;10(6):1769-73.
1990: B S Carter; C M Ewing; W S Ward; B F Treiger; Tilly W Aalders; Jack A Schalken; Jonathan I Epstein; William B Isaacs
Allelic loss of chromosomes 16q and 10q in human prostate cancer.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(22):8751-5.
1990: GO Oosterhof; G A Smits; A E de Ruyter; Jack A Schalken; F M Debruyne
In vivo effects of high energy shock waves on urological tumors: an evaluation of treatment modalities.
The Journal of urology 1990;144(3):785-9.
1990: R J van Moorselaar; A J Beniers; B T Hendriks; P H van der Meide; H Schellekens; F M Debruyne; Jack A Schalken
In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system.
The Journal of urology 1990;143(6):1247-51.
1990: Jack A Schalken
The Heinrich Warner Prize 1989: the use of differential hybridization analysis to identify markers for diagnosis of urogenital cancer.
European urology 1990;18 Suppl 2():52-7.
1990: Jack A Schalken; M J Bussemakers; F M Debruyne
Oncogene expression in prostate cancer.
Progress in clinical and biological research 1990;357():97-105.
1990: F M Debruyne; M P Franssen; A J Beniers; Jack A Schalken; P H de Mulder
New prospects in the management of metastatic renal cell carcinoma. Experimental and clinical data.
Progress in clinical and biological research 1990;350():243-55.
1990: GO Oosterhof; G A Smiths; J E deRuyter; Jack A Schalken; F M Debruyne
Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft.
Urological research 1990;18(6):419-24.
1989: Anton J M Roebroek; Gerard J M Martens; A J Duits; Jack A Schalken; A van Bokhoven; S S Wagenaar; Wim J M Van De Ven
Differential expression of the gene encoding the novel pituitary polypeptide 7B2 in human lung cancer cells.
Cancer research 1989;49(15):4154-8.
1989: GO Oosterhof; G A Smits; J E de Ruyter; R J van Moorselaar; Jack A Schalken; F M Debruyne
The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R3327 PAT-2 rat prostatic cancer cell-line. A potentiating effect on the in vitro cytotoxicity of vinblastin.
Urological research 1989;17(1):13-9.
1989: Frans C S Ramaekers; A P Verhagen; John T Isaacs; W F J Feitz; O Moesker; G Schaart; Jack A Schalken; G Peter Vooijs
Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system.
The Prostate 1989;14(4):323-39.
1988: A J Beniers; W P Peelen; B T Hendriks; Jack A Schalken; F M Debruyne
Effect of alpha- and gamma-interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro.
Seminars in surgical oncology 1988;4(3):195-8.
1988: Jack A Schalken; Ans M W van den Ouweland; F M Debruijne; Herbert F M Karthaus; Wim J M Van De Ven
Oncogenes and urological malignancies: implications for the future.
Urological research 1988;16(5):333-9.
1988: A J Beniers; W P Peelen; B T Hendriks; Jack A Schalken; J C Romijn; F M Debruyne
In vitro antiproliferative efficacy of interferon-alpha, -gamma and tumor necrosis factor on two human renal tumor xenografts.
Urological research 1988;16(4):309-14.
1988: A P Verhagen; Tilly W Aalders; Frans C S Ramaekers; F M Debruyne; Jack A Schalken
Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration.
The Prostate 1988;13(1):25-38.
1987: Jack A Schalken; Anton J M Roebroek; P P Oomen; S S Wagenaar; F M Debruyne; Henri P J Bloemers; Wim J M Van De Ven
fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas.
The Journal of clinical investigation 1987;80(6):1545-9.
1987: Herbert F M Karthaus; W F J Feitz; A P vd Meijden; Jack A Schalken; J L Beck; B T Hendriks; PH Jap; G Peter Vooijs; F M Debruyne; Frans C S Ramaekers
Multidisciplinary evaluation of rat renal cell carcinoma.
In vivo (Athens, Greece) 1987;1(6):335-41.
1987: Herbert F M Karthaus; W F J Feitz; Frans C S Ramaekers; J L Beck; B T Hendriks; Jack A Schalken; K H Kurth; PH Jap; F M Debruyne
Multiparameter analysis of four human renal cell carcinoma xenografts in nude mice.
In vivo (Athens, Greece) 1987;1(6):327-34.
1987: Anton J M Roebroek; Jack A Schalken; C Onnekink; Henri P J Bloemers; Wim J M Van De Ven
Structure of the feline c-fes/fps proto-oncogene: genesis of a retroviral oncogene.
Journal of virology 1987;61(6):2009-16.
1987: Ans M W van den Ouweland; J J Van Groningen; Jack A Schalken; H W Van Neck; Henri P J Bloemers; Wim J M Van De Ven
Genetic organization of the c-sis transcription unit.
Nucleic acids research 1987;15(3):959-70.
1987: Herbert F M Karthaus; M J G Bussemakers; Jack A Schalken; K H Kurth; W F J Feitz; F M Debruyne; Henri P J Bloemers; Wim J M Van De Ven
Expression of proto-oncogenes in xenografts of human renal cell carcinomas.
Urological research 1987;15(6):349-53.
1986: Anton J M Roebroek; Jack A Schalken; Jack Leunissen; C Onnekink; Henri P J Bloemers; Wim J M Van De Ven
Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein.
The EMBO journal 1986;5(9):2197-202.
1986: Anton J M Roebroek; Jack A Schalken; M J G Bussemakers; H van Heerikhuizen; C Onnekink; F M Debruyne; Henri P J Bloemers; Wim J M Van De Ven
Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene.
Molecular biology reports 1986;11(2):117-25.
1986: Herbert F M Karthaus; Jack A Schalken; W F J Feitz; F M Debruyne; Peter de Haan; Henri P J Bloemers; Wim J M Van De Ven
Expression of the human fes cellular oncogene in renal cell tumors.
Urological research 1986;14(3):123-7.
1985: Anton J M Roebroek; Jack A Schalken; J S Verbeek; Ans M W van den Ouweland; C Onnekink; Henri P J Bloemers; Wim J M Van De Ven
The structure of the human c-fes/fps proto-oncogene.
The EMBO journal 1985;4(11):2897-903.
1985: J S Verbeek; Ans M W van den Ouweland; Jack A Schalken; Anton J M Roebroek; C Onnekink; Henri P J Bloemers; Wim J M Van De Ven
Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene.
Gene 1985;35(1-2):33-43.